In this study, EIF5A2 expression, prognosis, mutation, and its relationship with tumor mutation burden (TMB), microsatellite instability (MSI), immunity, and drug sensitivity were studied from a pan-cancer perspective. This evidence concerns the gene EIF5A2 and cancer.